Vince & Associates Clinical Research has opened a multi-million dollar Clinical Pharmacology Research Unit that promises “a boutique hotel experience for the study volunteers and a first-class scientific research setting for the biopharmaceutical industry”.
The new US facility is the culmination of “years of planning and design” by a team of more than 50 clinical researchers led by Dr Brad Vince, president and medical director of Vince & Associates Clinical Research, the company notes.
Vince & Associates provides Phase I-IV clinical trial services to the pharmaceutical, biotechnology and medical device industries from its headquarters in Overland Park, Kansas.
In addition to the luxurious amenities, which Vince & Associates believes will enhance subject retention, the clinical pharmacology unit offers enhanced subject safety and security measures, coupled with the Vince & Associates’ Physician Research Model, whereby principal investigators lead and are “intimately” involved in all aspects of ongoing clinical studies, the company says.
The facility “is purpose-built for the complex trials our clients require to make earlier drug development decisions and advance their drugs to market more aggressively than ever before”, Dr Vince commented.
He cited full technical resources and medical expertise required for Phase I/IIa Proof of Concept studies, incorporating a single ascending dose, multiple ascending dose and a patient proof-of-concept study in a single protocol.